The Stem Cell Podcast

Ep. 74: “Diabetes Drug Discovery” Featuring Dr. Shuibing Chen

Sep 13, 2016
In this enlightening conversation, Dr. Shuibing Chen, a stem cell biologist at Weill Cornell Medical College, dives into cutting-edge research on diabetes. She discusses her use of CRISPR and human stem cells to model diabetes, focusing on gene-specific drug candidates. Chen reveals her team's findings on how specific gene knockouts impact insulin secretion and beta cell function. She also shares insights from a drug screen identifying an FDA-approved compound that could help rescue beta cell dysfunction, paving the way for personalized therapies.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

CRISPR + hPSCs Create Precise Disease Models

  • CRISPR plus human pluripotent stem cells enable gene-specific disease modeling for diabetes.
  • This platform reveals cellular mechanisms and creates targets for drug screening.
ANECDOTE

Career Pivot From Chemistry To Stem Cells

  • Shuibing Chen described leaving chemistry to join Doug Melton's lab to work on human stem cell differentiation.
  • That move led her to find small molecules directing pancreatic lineage and inspired her current lab focus.
INSIGHT

GWAS Genes Show Functional Beta-Cell Defects

  • Knocking out T2D-associated genes in hPSC-derived beta-like cells shows functional defects without affecting differentiation.
  • KCNJ11 and KCNQ1 knockouts impaired insulin secretion, validating the platform's relevance.
Get the Snipd Podcast app to discover more snips from this episode
Get the app